B-COS co-founder and chief executive Chiara Guidi has outlined how the Belgian startup moved precision-fermentation research from Ghent University into a commercial company. In an Investment Climate Podcast account published by vegconomist, Guidi described B-COS as a developer of carbohydrate bioactives intended to stimulate crops’ defenses and reduce dependence on chemical pesticides.
The central outcome was B-COS’s use of Ghent University’s Fast Lane program. According to vegconomist, its standardized arrangement offered founders low equity and royalty obligations alongside an exclusive, perpetual worldwide license. The publication reported that this approach shortened incorporation, but the unfamiliar structure also became a difficult element of investor negotiations.
B-COS emerged from 15 years of university work and was incorporated within one month rather than one year, according to vegconomist’s podcast summary. The company secured €1 million in venture and grant financing during its first year outside academia, vegconomist reported. Guidi’s team also conducted more than 100 discussions with potential customers before its pre-seed round, according to the publication.
The company is pursuing crop-protection products alongside biostimulants that could reach the market sooner, vegconomist reported. Remaining issues include the realities of Belgium’s grant system: the podcast said applicants may need committed capital before obtaining support from VLAIO. Guidi also based valuation decisions on a market containing only five or six potential acquirers, according to vegconomist.
CONCLUSION The B-COS account shows how university licensing terms can influence the financing of precision-fermentation spin-outs as much as their underlying research. The next points to watch are the company’s progress across its two product tracks and its ability to combine private investment with grant support.